Enhancing Drug Management, Cost Savings, and Staff Satisfaction in Anesthesiology: A Quality Improvement Project in a Chinese Tertiary Hospital
ConclusionThe quality improvement project has yielded remarkable positive outcomes, serving as a model worthy of reference and replication in similar healthcare settings. (Source: Advances in Therapy)
Source: Advances in Therapy - March 18, 2024 Category: Drugs & Pharmacology Source Type: research

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
ConclusionThis anchored ITC demonstrated a greater PFS benefit for D-Rd versus VRd in TIE patients with NDMM. In the absence of head-to-head trials comparing D-Rd and VRd, the present trial may help inform treatment selection in this patient population. (Source: Advances in Therapy)
Source: Advances in Therapy - March 18, 2024 Category: Drugs & Pharmacology Source Type: research

Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase  Inhibitor
ConclusionsFindings suggest that brexu-cel may offer clinically and statistically significant benefits regarding objective response, complete response, and progression-free survival compared to pirtobrutinib among patients with R/R MCL after prior cBTKi therapy. Given the short follow-up and high degree of censoring in BRUIN, an analysis incorporating updated BRUIN data may provide more definitive overall survival results. (Source: Advances in Therapy)
Source: Advances in Therapy - March 18, 2024 Category: Drugs & Pharmacology Source Type: research

Perioperative and Long-Term Outcomes in Patients Undergoing Synchronous Carotid Endarterectomy and Coronary Artery Bypass Grafting: A Single-Center Experience
ConclusionPatients undergoing synchronous CEA and CABG face an elevated risk of perioperative cardiovascular events, particularly an increased stroke risk in patients with symptomatic and bilateral ICA stenosis.Graphical Abstract available for this article.Graphical Abstract (Source: Advances in Therapy)
Source: Advances in Therapy - March 13, 2024 Category: Drugs & Pharmacology Source Type: research

Adverse Drug Events Observed with the Newly Approved Remimazolam in Comparison to Propofol for General Anesthesia in Patients Undergoing Surgery: A Meta-analysis
ConclusionOur current analysis showed that the newly approved remimazolam was apparently associated with significantly fewer adverse drug events in comparison to propofol for GA in patients undergoing surgery. Therefore, this new drug should be further studied and more research with larger population sizes should be carried out to confirm this hypothesis. (Source: Advances in Therapy)
Source: Advances in Therapy - March 13, 2024 Category: Drugs & Pharmacology Source Type: research

Correction to: The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
(Source: Advances in Therapy)
Source: Advances in Therapy - March 13, 2024 Category: Drugs & Pharmacology Source Type: research

Correction to: Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis
(Source: Advances in Therapy)
Source: Advances in Therapy - March 13, 2024 Category: Drugs & Pharmacology Source Type: research

Correction to: PRESTO 2: An International Survey to Evaluate Patients ’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly
(Source: Advances in Therapy)
Source: Advances in Therapy - March 13, 2024 Category: Drugs & Pharmacology Source Type: research

Comparison of Healthcare Costs for Women with Treated Versus Untreated Vasomotor Symptoms Due to Menopause
ConclusionsMost women with VMS due to menopause were not treated within 6  months following diagnosis. While both on- and off-label treatment increased the total cost of care compared with untreated controls, those increases were modest in magnitude and should not impede treatment for women who report symptom improvement as a result of treatment. (Source: Advances in Therapy)
Source: Advances in Therapy - March 11, 2024 Category: Drugs & Pharmacology Source Type: research

Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review
AbstractAdalimumab (ADL, Humira®, reference product), an anti-TNF- α biologic, has transformed the treatment of chronic, immune-mediated inflammatory diseases. However, the high cost of ADL therapy has driven the development of more affordable ADL biosimilars, agents with no clinically meaningful differences from the reference product. This review summarizes the p roduct attributes of reference ADL and the nine ADL biosimilars approved and available in the USA in relation to patient experience of injection-site pain (ISP). Product formulation, delivery volume and device features (e.g., type and needle gauge size) influen...
Source: Advances in Therapy - March 11, 2024 Category: Drugs & Pharmacology Source Type: research

The Humanistic and Economic Burden Associated with Major Depressive Disorder: A Retrospective Cross-Sectional Analysis
ConclusionThese results quantify the significant and diverse burdens associated with MDD and prior MDD medication treatment failure. (Source: Advances in Therapy)
Source: Advances in Therapy - March 11, 2024 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study
ConclusionsDirect transition to LEM may be a valid treatment option for patients with insomnia who are dissatisfied with current treatment.Trial RegistrationClinicalTrials.gov identifier, NCT04742699. (Source: Advances in Therapy)
Source: Advances in Therapy - March 9, 2024 Category: Drugs & Pharmacology Source Type: research

Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of Ixekizumab
ConclusionThe citrate-free ixekizumab formulation was preferred and well accepted by most patients who switched from the original ixekizumab formulation. Similar findings were seen for those newly initiating citrate-free ixekizumab. (Source: Advances in Therapy)
Source: Advances in Therapy - March 5, 2024 Category: Drugs & Pharmacology Source Type: research

Increased Nasal Blimp1  + Treg Cells After Sublingual Immunotherapy Reflect the Efficacy of Treatment in Allergic Rhinitis
ConclusionElevated nasal Blimp1  + Treg cells serve as a predictive biomarker for SLIT responsiveness in pediatric AR. Their influence on immunotherapy effectiveness contributes to a nuanced understanding of SLIT mechanisms, allowing for disease stratification and personalized treatment plans. This study offers scientific supp ort for predicting SLIT efficacy, enhancing the prospects of improved treatment outcomes in AR. (Source: Advances in Therapy)
Source: Advances in Therapy - March 5, 2024 Category: Drugs & Pharmacology Source Type: research

Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study
ConclusionDespite improved efficacy of 1L systemic therapies, CSEs remain a concern for patients with uHCC, as well as an economic burden to the healthcare system. Newer treatments that reduce the risk of CSEs, while improving long-term survival in patients with uHCC, are warranted. (Source: Advances in Therapy)
Source: Advances in Therapy - March 5, 2024 Category: Drugs & Pharmacology Source Type: research